Skip to content

Reflux Characteristics and Esophageal Motility in Reflux Esophagitis with Chronic Atrophic Gastritis: A Case-Control Study Based on HRM and MII-pH

Reflux Characteristics and Esophageal Motility in Reflux Esophagitis with Chronic Atrophic Gastritis: A Case-Control Study Based on HRM and MII-pH

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125790
Enrollment
Unknown
Registered
2026-06-01
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux Esophagitis

Interventions

Chronic atrophic gastritis + reflux esophagitis observation group:None
Observation group of non-chronic atrophic gastritis + reflux esophagitis:None

Sponsors

Liupanshui People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 - 75 years old, gender not restricted; 2. Within the past six months, confirmed by gastroscopy as LA A/B/C/D grade reflux esophagitis (Los Angeles LA classification); 3. Agree to complete HRM and MII-pH tests as well as questionnaire collection; 4. Agree to participate in the prospective follow-up and data collection, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: If the subject has any of the following conditions, they will be excluded: 1. Special types of gastritis (autoimmune gastritis/chemical/choledocholitic atrophic gastritis); 2. Any other structural or mucosal diseases of the esophagus (such as Barrett's esophagus, eosinophilic esophagitis, esophageal stenosis, esophageal varices, malignant tumors, or a history of chemical/thermal/radiation injury); 3. Systemic diseases that affect esophageal-gastrointestinal motility (such as systemic sclerosis, dermatomyositis, systemic lupus erythematosus, amyloidosis), uncontrolled diabetes (fasting blood glucose >= 11.1 mmol/L), severe pulmonary, cardiovascular or cerebrovascular diseases, obvious liver and kidney dysfunction or severe mental illness; 4. Previous history of gastric or esophageal surgery (including EMR/ESD); 5. Pregnant, lactating or planning to become pregnant during the study period; 6. Within the past 4 weeks, received eradication treatment or drugs that affect motility/ reflux and failed to follow the withdrawal requirements.

Design outcomes

Primary

MeasureTime frame
Proportion of non-acid reflux events;

Secondary

MeasureTime frame
Acid exposure time (AET);Total reflux events;Lower esophageal sphincter pressure (LES pressure);Proportion of ineffective esophageal motility (IEM);

Countries

China

Contacts

Public ContactYushi Zhou

Liupanshui People's Hospital

yushizhou0428@gmail.com+86 858 832 1422

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026